Filter posts

Dealing with Rejection, the Regulatory Kind

The ubiquitous CRL in biotech has made its way into the news headlines again. But …

BIO Europe Spring 2012 - Opening Remarks

For Monday’s Opening Remarks at BIO Europe Spring 2012, I covered the following topics: Public …

Does Biotech History Repeat?

According to Mark Twain, “History does not repeat itself, but it does rhyme”. Little did he …

Update: Indices, IPOs, and New Drug Approvals

Here is a look at year to date (YTD) numbers through the end of February …

Oncology Clinical Trials - Secrets of Success

At last year’s BIO CEO & Investor Conference, BIO and BioMedTracker presented data showing that …

BIO CEO 2012 Opening Remarks

The 14th Annual BIO CEO & Investor Conference started with a busy turnout Monday at …

A Very Big BTK January

We all heard reports that January was a great start to 2012 for the stock …

Reviewing the drug class of 2011

The drug class of 2011 was larger than the past few graduating classes. We count …

Venture Capital increases in 2011, but...

The National Venture Capital Association (NVCA) has released their 4Q 2011 numbers for biotech venture …

Sizing up the NBI in 2011

How did the Nasdaq Biotechnology Index (NBI) perform in 2011 relative to other sectors? Second …